Crystalline solids

被引:652
作者
Vippagunta, SR
Brittain, HG
Grant, DJW
机构
[1] Univ Minnesota, Coll Pharm, Dept Pharmaceut, Minneapolis, MN 55455 USA
[2] Ctr Pharmaceut Phys, Milford, NJ 08848 USA
关键词
crystallinity; polymorphs; hydrates; solvates; formulation; drug substance; phase transformation; characterization;
D O I
10.1016/S0169-409X(01)00097-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many drugs exist in the crystalline solid state due to reasons of stability and ease of handling during the various stages of drug development. Crystalline solids can exist in the form of polymorphs, solvates or hydrates, phase transitions such as polymorph interconversion, desolvation of solvate, formation of hydrate and conversion of crystalline to amorphous form may occur during various pharmaceutical processes, which may alter the dissolution rate and transport characteristics of the drug. Hence it is desirable to choose the most suitable and stable form of the drug in the initial stages of drug development. The current focus of research in the solid-state area is to understand the origins of polymorphism at the molecular level, and to predict and prepare the most stable polymorph of a drug. The recent advances in computational tools allow the prediction of possible polymorphs of the drug from its molecular structure. Sensitive analytical methods are being developed to understand the nature of polymorphism and to characterize the various crystalline forms of a drug in its dosage form. The aim of this review is to emphasize the recent advances made in the area of prediction and characterization of polymorphs and solvates, to address the current challenges faced by pharmaceutical scientists and to anticipate future developments. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:3 / 26
页数:24
相关论文
共 102 条
[1]   Solid state assay of ranitidine HCl as a bulk drug and as active ingredient in tablets using DRIFT spectroscopy with artificial neural networks [J].
Agatonovic-Kustrin, S ;
Tucker, IG ;
Schmierer, D .
PHARMACEUTICAL RESEARCH, 1999, 16 (09) :1477-1482
[2]   Powder diffractometric assay of two polymorphic forms of ranitidine hydrochloride [J].
Agatonovic-Kustrin, S ;
Wu, V ;
Rades, T ;
Saville, D ;
Tucker, IG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 184 (01) :107-114
[3]  
[Anonymous], 1993, J MOL GRAPH MODEL
[4]   Sulfathiazole polymorphism studied by magic-angle spinning NMR [J].
Apperley, DC ;
Fletton, RA ;
Harris, RK ;
Lancaster, RW ;
Tavener, S ;
Threlfall, TL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (12) :1275-1280
[5]  
BANDYOPADHYAY R, 1998, P WORLD C PART TECHN, P7
[6]  
Bernstein J, 1999, ANGEW CHEM INT EDIT, V38, P3440, DOI 10.1002/(SICI)1521-3773(19991203)38:23<3440::AID-ANIE3440>3.0.CO
[7]  
2-#
[8]   Crystal chemistry and solvent effects in polymorphic systems - Sulfathiazole [J].
Blagden, N ;
Davey, RJ ;
Lieberman, HF ;
Williams, L ;
Payne, R ;
Roberts, R ;
Rowe, R ;
Docherty, R .
JOURNAL OF THE CHEMICAL SOCIETY-FARADAY TRANSACTIONS, 1998, 94 (08) :1035-1044
[9]   Disappearing polymorphs and the role of reaction by-products: the case of sulphathiazole [J].
Blagden, N ;
Davey, RJ ;
Rowe, R ;
Roberts, R .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 172 (1-2) :169-177
[10]  
BORKA L, 1990, ACTA PHARM JUGOSL, V40, P71